Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Chaza Alaji: The Prothrombotic and Hemorrhagic Spectrum of Tuberculosis
Chaza Alaji/LinkedIn
Nov 7, 2026, 02:06

Chaza Alaji: The Prothrombotic and Hemorrhagic Spectrum of Tuberculosis

Chaza Alaji, Medical Laboratory Specialist and Supervisor at Privat University-Private Laboratory-General Hospital, shared a post on LinkedIn:

“Pulmonary and Extrapulmonary Tuberculosis: Reappraising Infection-Associated Bleeding and Thrombotic Mechanisms.

Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global health challenge.

Beyond pulmonary and extrapulmonary disease, TB can profoundly affect hemostasis, creating a paradoxical clinical picture: an increased risk of both bleeding and thrombosis.

1. TB-Associated Bleeding: Vascular and Hematological Mechanisms

Hemoptysis is one of the most clinically significant bleeding manifestations of pulmonary TB.

It may result from tissue destruction, cavitation, and erosion of adjacent pulmonary vessels.

A particularly serious complication is Rasmussen’s aneurysm, a pulmonary artery pseudoaneurysm developing within or adjacent to a tuberculous cavity.

Its rupture can cause life-threatening hemoptysis.

Systemic bleeding may also occur in severe or disseminated TB due to:

  • Disseminated intravascular coagulation (DIC), with consumption of platelets and coagulation factors.
  • Thrombocytopenia, occasionally immune-mediated or associated with bone marrow involvement.
  • Hepatic dysfunction and severe systemic inflammation, which may disrupt coagulation balance.

2. TB-Associated Thrombosis: A Prothrombotic State

Active TB is associated with increased thrombotic risk, particularly venous thromboembolism (VTE).

Systemic inflammation activates coagulation pathways and endothelial cells, increases fibrinogen and other procoagulant factors, and may reduce natural anticoagulant activity.

Immobility, hospitalization, and comorbidities further contribute to thrombosis.

Clinical complications include:

  • Deep vein thrombosis (DVT).
  • Pulmonary embolism (PE).
  • Cerebral ischemic events, particularly in tuberculous meningitis, where inflammatory cerebral vasculitis can cause arterial narrowing, thrombosis, and infarction.

3. Laboratory Assessment and Clinical Monitoring

Evaluation should be guided by the clinical presentation and may include:

  • Complete blood count and platelet count.
  • PT/INR and aPTT.
  • Fibrinogen and D-dimer when DIC or thrombosis is suspected.
  • Liver function tests and markers of hemolysis when indicated.
  • Doppler ultrasonography or CT pulmonary angiography for suspected thrombosis.

No single laboratory parameter establishes TB-associated coagulopathy; results require clinical interpretation.

4. Treatment Advances and Hematological Considerations

WHO guidance continues to support shorter, all-oral regimens for eligible patients with drug-resistant TB, including BPaLM (bedaquiline, pretomanid, linezolid, and moxifloxacin).

Regimen selection depends on resistance patterns, disease characteristics, and patient eligibility.

Importantly, linezolid may cause thrombocytopenia and bone marrow suppression, requiring hematological monitoring.

Rifampicin can also interact significantly with anticoagulants,

complicating the management of patients with concurrent thrombosis.”

Chaza Alaji: The Prothrombotic and Hemorrhagic Spectrum of Tuberculosis

Stay updated with Hemostasis Today.

Chaza Alaji DIC Disseminated Intravascular Coagulation Extrapulmonary Tuberculosis Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine Mycobacterium tuberculosis Pulmonary Tuberculosis rifampicin VTE
NewsFeed